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Population — 806 patients were admitted for sustained VT between 
1978 and 2008.
Methods — The following studies were performed: recording of 
ECG, signal averaged ECG, Holter monitoring, exercise testing 
(when possible), echocardiography, right angiography in patients 
with right VT, coronary angiography in patients older than 40 years 
and electrophysiological study.
Results — 74 patients (9 %), aged from 11 to 75 years (mean 46±18), 
45 men, 29 women had normal echocardiogram and hemodynamic 
study. Right ventricular out ow tract (RVOT) VT was noted in 42 
patients, verapamil-sensitive VT in 23 ; VT’s were right and left in 3 
patients, related to a bundle branch reentry in 1, of undetermined 
origin in 4 patients. VT developed at exercise testing in 15 patients 
and was inducible or occurred with isoproterenol in 54 patients 
(73 %). Erroneous diagnosis of supraventricular tachycardia with 
aberrancy was initially made in 5 patients. Beta blockers and/or 
antiarrhythmic drugs were initially prescribed. De brillator was 
implanted in one patient with syncopal RVOT-VT and 2 for a false 
diagnosis of right ventricle dysplasia made in 2002 at beginning of 
MRI. Catheter ablation for recurrent VT was performed in 3 patients 
with failure in one and in 1 patient for its job. Three patients were 
lost of view during follow—up (mean 11.5±6.6 years); remaining 
patients, but one are alive without recurrent VT and without 
drugs in half of them ; 1 patient died from non cardiac cause. One 
patient developed dilated cardiomyopathy ; 2 had permanent atrial 
 brillation.
Conclusions — VT in patients without apparent HD after conventional 
studies (echocardiography, hemodynamic study) represented 9 % of 
VT and required rarely a non medical treatment.
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Free fatty acids are the primary substrate used by the heart to generate 
cellular ATP. Carnitine, acylcarnitine and carnitine-transferase 
are essential for normal metabolism of long-chain fatty acids in 
heart. Some of the arrhythmias observed following an ischaemia 
are attributed to an accumulation of long-chain acylcarnitine into 
ad out the cells. It has also been observed that a de ciency in a 
carnitine transporter, OCTN2, normally found in heart, muscle and 
kidney, leads to a reduced plasma carnitine and acylcarnitine level. 
Such pathology was associated with the occurrence of ventricular 
 brillation and eventually to sudden death. All these data suggest 
that acyl-carnitine (Acyl-CARs) can regulate ion channels.
We studied the effects of different acyl-CARs at different 
concentrations on the hERG channel activity (IhERG) which is known 
to participate to lethal arrhythmias.
HEK293 cells stably expressing hERG were studied in patch clamp. 
Acyl-CAR derivatives from medium — (C8 and C10) and long-chain 
(C16 and C18:1) fatty acids were applied intra- and extracellularly 
at different concentrations.
C8-CAR and C10-CAR had no effect at 3 m and 30 m whether they 
are applied intra- or extracellularly. C16-CAR and C18-CAR had no 
effect on the current when applied intracellularly. Extracellularly, 
3 m C16-CAR or C18-CAR induced an increase of the current 
amplitude associated with different effects on the activation and 
availability properties. At this concentration, the long-chain acyl-
CAR induced also a speeding of deactivation kinetic.
Long-chain acyl-CARs, but not medium-chain, regulate extracellularly 
IhERG. When their level varies during diseases like primary systemic 
carnitine de ciency or ischaemia, there must be an impact on the 
action potential which can explain some of the cardiac arrhythmias 
observed.
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Rationnel — La maladie de Steinert (DM1) est une maladie 
systémique associée à un risque élevé de mort subite en rapport 
avec des troubles conductifs et des arythmies ventriculaires. Le 
mécanisme de ces morts subites n’est pas connu. Notre objectif 
était de déterminer si le syndrome de Brugada est impliqué dans 
ces complications.
Méthode — Nous avons analysé les électrocardiogrammes de 500 
patients atteints de maladie de Steinert. Les patients ayant un 
tracé ECG avec un Brugada de type 1 ont béné cié d’un séquençage 
du gène SCN5A et d’un bilan cardiaque comprenant un holter ECG, 
une échocardiographie et une exploration électrophysiologique.
Résultats — Un ECG avec un aspect de Brugada de type 1 a été 
identi é chez 7 patients, soit une prévalence 80 fois plus élevée 
que dans la population générale. Le séquençage de SCN5A était 
normal chez tous les patients. Un patient a fait une mort subite 
en rapport avec une  brillation ventriculaire et la stimulation 
ventriculaire programmée a déclenché des tachycardies 
ventriculaires polymorphes chez 5 patients.
Conlusion — La prévalence du syndrome de Brugada est plus élevée 
chez les patients DM1 que dans la population générale. Les patients 
présentant l’association de ces deux anomalies semblent exposés à 
un risque élevé d’arythmies ventriculaires sévères.
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Introduction — The major determinant of atrial  brillation initiation 
is focal  ring within the muscular portion of the pulmonary veins. 
We hypothesized that Interstitial Cajal cells, a known type of pace-
